See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

SCD Phase 2a trial starts dosing HBI-002 liquid carbon monoxide

Summary by Sickle Cell Disease News
The first patient with SCD has been dosed in a clinical trial of HBI-002, an experimental, low-dose liquid formulation of carbon monoxide.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

Sickle Cell Disease NewsSickle Cell Disease News

SCD Phase 2a trial starts dosing HBI-002 liquid carbon monoxide

The first patient with SCD has been dosed in a clinical trial of HBI-002, an experimental, low-dose liquid formulation of carbon monoxide.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sickle Cell Disease News broke the news in on Thursday, July 31, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Panama icon

Panama

News
For You
SearchBlindspotLocal